Home Pharmaceutics ASCO 25: Roche places Itovebi marker in breast cancer

ASCO 25: Roche places Itovebi marker in breast cancer

by Newsroom



Roche’s Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set to consolidate its position.

Itovebi (inavolisib) has an FDA green light as part of a combination regimen for patients with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, moving it up the treatment pathway ahead of Novartis’ rival PIK3 inhibitor Piqray/Vijoice (alpelisib) which has been cleared since 2019 as a second-line therapy and is not being developed as a…



Source link

You may also like

About Us

Pharma Newswire™ aggregates, publishes and distributes news in the Pharmaceutical Industry. In association with EmailWire, Pharma Newswire™ provides press release distribution services in the pharmaceutical sector. Press releases are disseminated to journalists, experts, investors, trade publications and other related media outlets. To send a press release, contact us through the following messaging apps:

Pharma Newswire™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC